Answers are grounded in this paper and cite their sources.
Background: Caffeic acid phenethyl ester (CAPE) exhibits reported anticancer activity, but its potential molecular targets in breast cancer remain incompletely characterized. Methods: Network pharmacology and comparative transcriptomic, genomic, proteomic, and clinicopathological analyses were performed to prioritize candidate targets. Molecular docking, 100 ns molecular dynamics simulations, MM-GBSA calculations, and in silico CRISPR/Cas9 guide design were subsequently conducted. Results: ESR1, PIK3CA, EGFR, MAPK1, and PGR were prioritized as candidate proteins. Expression analyses revealed heterogeneous molecular patterns, without significant overall-survival associations after multiple-testing correction. ESR1 exhibited a predicted docking score of −6.12 kcal/mol and was selected for molecular dynamics analysis. CAPE remained associated with the ESR1 binding region during the simulated trajectory, although the initially predicted Asp351 hydrogen bond was not maintained. MM-GBSA estimates were less favourable for CAPE–ESR1 (−59.43 ± 4.28 kcal/mol) than for the 4-hydroxytamoxifen–ESR1 reference complex (−70.43 ± 3.80 kcal/mol). Conclusions: The findings identify computationally prioritized candidate targets and provide testable hypotheses concerning CAPE-associated molecular interactions in breast cancer. Experimental studies are required to establish direct target engagement and biological relevance.
No takes yet. Share an insight, caveat, or question.
Karwa et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: